Country: Ամերիկայի Միացյալ Նահանգներ
language: անգլերեն
source: NLM (National Library of Medicine)
LOPERAMIDE HYDROCHLORIDE (UNII: 77TI35393C) (LOPERAMIDE - UNII:6X9OC3H4II)
Contract Pharmacy Services-PA
LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE 2 mg
ORAL
PRESCRIPTION DRUG
Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. Loperamide hydrochloride capsules are contraindicated in: - pediatric patients less than 2 years of age due to the risks of respiratory depression and serious cardiac adverse reactions (see WARNINGS). - patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. - patients with abdominal pain in the absence of diarrhea. - patients with acute dysentery, which is characterized by blood in stools and high fever. - patients with acute ulcerative colitis. - patients with bacterial enterocolitis caused by invasive organisms including Salmonella , Shigella ,
Loperamide Hydrochloride Capsules, USP are available containing 2 mg of loperamide hydrochloride, USP. The capsule is a hard-shell gelatin capsule with a light brown opaque cap and a light brown opaque body filled with white to off-white powder blend. The capsule is axially printed with MYLAN over 2100 in black ink on both the cap and the body. They are available as follows: NDC 67046-456-07 blisterpacks of 7 NDC 67046-456-14 blisterpacks of 14 NDC 67046-456-15 blisterpacks of 15 NDC 67046-456-20 blisterpacks of 20 NDC 67046-456-21 blisterpacks of 21 NDC 67046-456-28 blisterpacks of 28 NDC 67046-456-30 blisterpacks of 30 NDC 67046-456-60 blisterpacks of 60 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Revised: 11/2016 LOP:R14 Repackaged by: Contract Pharmacy Services-PA 125 Titus Ave Suite 200 Warrington, PA 18976 USA
Abbreviated New Drug Application
LOPERAMIDE HYDROCHLORIDE- LOPERAMIDE HYDROCHLORIDE CAPSULE CONTRACT PHARMACY SERVICES-PA ---------- LOPERAMIDE 2 MG 456 WARNING: TORSADES DE POINTES AND SUDDEN DEATH 1. ● CASES OF TORSADES DE POINTES, CARDIAC ARREST, AND DEATH HAVE BEEN REPORTED WITH THE USE OF A HIGHER THAN RECOMMENDED DOSAGE OF LOPERAMIDE HYDROCHLORIDE CAPSULES (SEE WARNINGS AND OVERDOSAGE). 2. ● LOPERAMIDE HYDROCHLORIDE CAPSULES ARE CONTRAINDICATED IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE (SEE CONTRAINDICATIONS). 3. ● AVOID LOPERAMIDE HYDROCHLORIDE CAPSULES DOSAGES HIGHER THAN RECOMMENDED IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER DUE TO THE RISK OF SERIOUS CARDIAC ADVERSE REACTIONS (SEE DOSAGE AND ADMINISTRATION). DESCRIPTION Loperamide hydrochloride, 4-(p-chlorophenyl)-4-hydroxy-N, N-dimethyl-α,α-diphenyl-1- piperidinebutyramide monohydrochloride, is a synthetic antidiarrheal for oral use. Loperamide hydrochloride is available in 2 mg capsules. Loperamide hydrochloride capsules, USP contain the following inactive ingredients: black iron oxide, colloidal silicon dioxide, gelatin, lactose monohydrate, magnesium stearate, microcrystalline cellulose, red iron oxide, sodium lauryl sulfate, sodium starch glycolate, titanium dioxide, and yellow iron oxide. In addition, the black imprinting ink also contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, propylene glycol, and shellac glaze. CLINICAL PHARMACOLOGY MECHANISM OF ACTION _In vitro _and animal studies show that loperamide hydrochloride capsules act by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing propulsive peristalsis, and increasing intestinal transit time. Loperamide increases the tone of the anal sphincter, thereby reducing incontinence and urgency. PHARMACODYNAMICS L read_full_document